Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Cited by (1,049)

Items 1,001–1,049 of 1,049

1. Somatic mutation of fibroblast growth factor receptor‐3 ( <i>FGFR3</i> ) defines a distinct morphological subtype of high‐grade urothelial carcinoma
   Al‐Ahmadie, Hikmat A, Iyer, Gopa, Janakiraman, Manickam, Lin, Oscar, Heguy, Adriana, Tickoo, Satish K., Fine, Samson W., Gopalan, Anuradha, Chen, Ying‐bei, Balar, Arjun et al. · 2011 · The Journal of Pathology
2. KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy
   Guan, Ji-lin, Zhong, Wen-zhao, An, She-juan, Yang, Jin-ji, Su, Jian, Chen, Zhi-hong, Yan, Hong-hong, Chen, Zhi-yong, Huang, Zhi-min, Zhang, Xu-chao et al. · 2013 · Annals of Surgical Oncology
3. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis
   Kuan, Feng-Che, Kuo, Liang-Tseng, Chen, Min-Chi, Yang, Cheng-Ta, Shi, Chung-Sheng, Teng, David, Lee, Kuan-Der · 2015 · British Journal of Cancer
4. Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors
   Hofheinz, Ralf-Dieter, Deplanque, Gaël, Komatsu, Yoshito, Kobayashi, Yoshimitsu, Ocvirk, Janja, Racca, Patrizia, Guenther, Silke, Zhang, Jun, Lacouture, Mario E., Jatoi, Aminah · 2016 · The Oncologist
5. AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients
   Xu, Xiao, Mao, Long, Xu, Wanhong, Tang, Wei, Zhang, Xiaoying, Xi, Biao, Xu, Rongda, Fang, Xin, Liu, Jia, Fang, Ce et al. · 2016 · Molecular Cancer Therapeutics
6. PROTAC therapy as a new targeted therapy for lung cancer
   Li, Jennifer W., Zheng, Guangrong, Kaye, Frederic J., Wu, Lizi · 2023 · Molecular Therapy
7. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases
   Mak, K. S., Gainor, J. F., Niemierko, A., Oh, K. S., Willers, H., Choi, N. C., Loeffler, J. S., Sequist, L. V., Shaw, A. T., Shih, H. A. · 2015 · Neuro-Oncology
8. Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions
   Piotrowska, Z., Costa, D.B., Oxnard, G.R., Huberman, M., Gainor, J.F., Lennes, I.T., Muzikansky, A., Shaw, A.T., Azzoli, C.G., Heist, R.S. et al. · 2018 · Annals of Oncology
9. NSCLC and HER2: between lights and shadows
   Ricciardi, Giuseppina Rosaria Rita, Russo, Alessandro, Franchina, Tindara, Ferraro, Giuseppa, Zanghì, Mariangela, Picone, Antonio, Scimone, Antonino, Adamo, Vincenzo · 2014 · Journal of Thoracic Oncology
10. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer
    Villaflor, Victoria, Won, Brian, Nagy, Rebecca, Banks, Kimberly, Lanman, Richard B., Talasaz, AmirAli, Salgia, Ravi · 2016 · Oncotarget
11. Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring &lt;em&gt;EGFR&lt;/em&gt; exon 20 mutations
    Cheng, Guoping, Song, Zhengbo, Chen, Dan · 2016 · OncoTargets and Therapy
12. MEK inhibition in non-small cell lung cancer
    Stinchcombe, Thomas E., Johnson, Gary L. · 2014 · Lung Cancer
13. Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
    Kuiper, J L, Hashemi, S M S, Thunnissen, E, Snijders, P J F, Grünberg, K, Bloemena, E, Sie, D, Postmus, P E, Heideman, D A M, Smit, E F · 2016 · British Journal of Cancer
14. Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs
    Melosky, Barbara, Hirsh, Vera · 2014 · Frontiers in Oncology
15. A genetic interaction analysis identifies cancer drivers that modify EGFR dependency
    Liao, Sida, Davoli, Teresa, Leng, Yumei, Li, Mamie Z., Xu, Qikai, Elledge, Stephen J. · 2017 · Genes &amp; Development
16. Clinical Outcomes in Non–Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR
    Chung, Kuei-Pin, Wu, Shang-Gin, Wu, Jenn-Yu, Yang, James Chih-Hsin, Yu, Chong-Jen, Wei, Pin-Fei, Shih, Jin-Yuan, Yang, Pan-Chyr · 2012 · Clinical Cancer Research
17. Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts
    Zhang, Guochun, Wang, Yulei, Chen, Bo, Guo, Liping, Cao, Li, Ren, Chongyang, Wen, Lingzhu, Li, Kai, Jia, Minghan, Li, Cheukfai et al. · 2019 · Annals of Translational Medicine
18. Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer
    Theard, Patricia L, Sheffels, Erin, Sealover, Nancy E, Linke, Amanda J, Pratico, David J, Kortum, Robert L · 2020 · eLife
19. Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations
    Krawczyk, Pawel, Kowalski, Dariusz M., Ramlau, Rodryg, Kalinka-Warzocha, Ewa, Winiarczyk, Kinga, Stencel, Katarzyna, Powrózek, Tomasz, Reszka, Katarzyna, Wojas-Krawczyk, Kamila, Bryl, Maciej et al. · 2017 · Oncology Letters
20. Pharmacogenetic Associations with Vascular Endothelial Growth Factor Inhibition in Participants with Neovascular Age-related Macular Degeneration in the IVAN Study
    Lotery, Andrew J., Gibson, Jane, Cree, Angela J., Downes, Susan M., Harding, Simon P., Rogers, Chris A., Reeves, Barnaby C., Ennis, Sarah, Chakravarthy, Usha · 2013 · Ophthalmology
21. United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies
    Jeong, Woondong, Doroshow, James H., Kummar, Shivaani · 2013 · Current Problems in Cancer
22. Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer
    Spaans, Johanna N., Goss, Glenwood D. · 2014 · Frontiers in Oncology
23. EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib
    Jenkins, Suzanne, Chih-Hsin Yang, James, Jänne, Pasi A., Thress, Kenneth S., Yu, Karen, Hodge, Rachel, Weston, Susie, Dearden, Simon, Patel, Sabina, Cantarini, Mireille et al. · 2017 · Journal of Thoracic Oncology
24. The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: a single South East Asian laboratory's analysis of 670 cases
    Pang, B., Matthias, D., Ong, C. W., Dhewar, A. N., Gupta, S., Lim, G. L., Nga, M. E., Seet, J. E., Qasim, A., Chin, T. M. et al. · 2012 · Cytopathology
25. Clinical protein science in translational medicine targeting malignant melanoma
    Gil, Jeovanis, Betancourt, Lazaro Hiram, Pla, Indira, Sanchez, Aniel, Appelqvist, Roger, Miliotis, Tasso, Kuras, Magdalena, Oskolas, Henriette, Kim, Yonghyo, Horvath, Zsolt et al. · 2019 · Cell Biology and Toxicology
26. Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer
    Wu, Jenn-Yu, Shih, Jin-Yuan · 2016 · OncoTargets and Therapy
27. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics
    Tan, Daniel S.W., Camilleri‐Broët, Sophie, Tan, Eng Huat, Alifano, Marco, Lim, Wan‐Teck, Bobbio, Antonio, Zhang, Shenli, Ng, Quan‐Sing, Ang, Mei‐Kim, Iyer, N. Gopalakrishna et al. · 2014 · International Journal of Cancer
28. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non–Small-cell Lung Cancer
    Lin, Yen-Ting, Liu, Yi-Nan, Wu, Shang-Gin, Yang, James Chih-Hsin, Shih, Jin-Yuan · 2017 · Clinical Lung Cancer
29. EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models
    Venugopalan, Abhilash, Lee, Min-Jung, Niu, Gang, Medina-Echeverz, José, Tomita, Yusuke, Lizak, Martin J., Cultraro, Constance M., Simpson, Robert Mark, Chen, Xiaoyuan, Trepel, Jane B. et al. · 2016 · Oncotarget
30. A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
    Zhang, Jian, Cao, Junning, Li, Jin, Zhang, Yifan, Chen, Zhiyu, Peng, Wei, Sun, Si, Zhao, Naiqing, Wang, Jiachen, Zhong, Dafang et al. · 2014 · Journal of Hematology &amp; Oncology
31. Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer
    Yap, Timothy A., Macklin-Doherty, Aislinn, Popat, Sanjay · 2017 · European Journal of Cancer
32. What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis
    Bronte, Giuseppe, Rolfo, Christian, Passiglia, Francesco, Rizzo, Sergio, Gil-Bazo, Ignacio, Fiorentino, Eugenio, Cajozzo, Massimo, Van Meerbeeck, Jan P., Lequaglie, Cosimo, Santini, Daniele et al. · 2015 · Critical Reviews in Oncology/Hematology
33. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients
    Pérez-Ramírez, Cristina, Cañadas-Garre, Marisa, Alnatsha, Ahmed, Villar, Eduardo, Delgado, Juan Ramón, Faus-Dáder, María José, Calleja-Hernández, Miguel ÿngel · 2016 · Pharmacological Research
34. Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Jain, Amit, Lim, Cindy, Gan, Eugene MingJin, Ng, David Zhihao, Ng, Quan Sing, Ang, Mei Kim, Takano, Angela, Chan, Kian Sing, Tan, Wu Meng, Kanesvaran, Ravindran et al. · 2015 · PLOS ONE
35. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy
    Ying, Hou-Qun, Chen, Jie, He, Bang-Shun, Pan, Yu-Qin, Wang, Feng, Deng, Qi-Wen, Sun, Hui-Ling, Liu, Xian, Wang, Shu-Kui · 2015 · Scientific Reports
36. BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations
    Cardona, Andrés F., on behalf of the CLICaP, Rojas, Leonardo, Wills, Beatriz, Arrieta, Oscar, Carranza, Hernán, Vargas, Carlos, Otero, Jorge, Corrales-Rodriguez, Luis, Martín, Claudio et al. · 2016 · Oncotarget
37. Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit
    Ning, Wenjuan, Marti, Thomas M., Dorn, Patrick, Peng, Ren-Wang · 2022 · Frontiers in Oncology
38. Dacomitinib in lung cancer: a &amp;ldquo;lost generation&amp;rdquo; EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou, Sai-Hong, Soo, Ross · 2015 · Drug Design, Development and Therapy
39. SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC
    Yuan, Man, Xu, Lin-feng, Zhang, Juan, Kong, Si-yuan, Wu, Man, Lao, Yuan-zhi, Zhou, Hua, Zhang, Li, Xu, Hongxi · 2019 · Frontiers in Oncology
40. Dynamic monitoring of EGFR mutations in circulating cell-free DNA for EGFR-mutant metastatic patients with lung cancer: Early detection of drug resistance and prognostic significance
    Ni, Jianjiao, Weng, Linqian, Liu, Yi, Sun, Zhao, Bai, Chunmei, Wang, Yingyi · 2017 · Oncology Letters
41. EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: a meta-analysis
    Zhang, Qiong, Dai, Hong-Hai, Dong, Hong-Yun, Sun, Cheng-Tao, Yang, Zhe, Han, Jun-Qing · 2014 · Lung Cancer
42. Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer
    Mendes, Cindy, Serpa, Jacinta · 2019 · Antioxidants
43. Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer
    Liu, Xiaoke, Hong, Lingzhi, Nilsson, Monique, Hubert, Shawna Marie, Wu, Shuhong, Rinsurongkawong, Waree, Lewis, Jeffery, Spelman, Amy, Roth, Jack, Swisher, Steven et al. · 2020 · Lung Cancer
44. Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations
    Frega, Stefano, Lorenzi, Martina, Fassan, Matteo, Indraccolo, Stefano, Calabrese, Fiorella, Favaretto, Adolfo, Bonanno, Laura, Polo, Valentina, Zago, Giulia, Lunardi, Francesca et al. · 2017 · Oncotarget
45. Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
    Shi, Yuankai, Wu, Lin, Ji, Yinghua, Chen, Gongyan, Li, Baolan, Bi, Minghong, Yang, Runxiang, Miao, Liyun, Zhang, Guojun, Gao, Hongjun et al. · 2025 · The Lancet Respiratory Medicine
46. Metastatic Lung Tumors from Colorectal Cancer with &lt;i&gt;EGFR&lt;/i&gt; Mutations That Responded to Osimertinib
    Yanagisawa, Atsushi, Kinehara, Yuhei, Kijima, Ryo, Tanaka, Masaki, Ninomiya, Ryusuke, Jokoji, Ryu, Tachibana, Isao · 2023 · Internal Medicine
47. The role of systemic and targeted therapies in brain metastases
    Franceschi, Enrico, Bartolotti, Marco, Poggi, Rosalba, Battista, Monica Di, Palleschi, Dario, Brandes, Alba A · 2014 · Expert Review of Anticancer Therapy
48. The Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Predicting Treatment Response Before EGFR TKI Treatment in Patients with Advanced Lung Adenocarcinoma
    Agüloğlu, Nurşin, Akyol, Murat, Kömek, Halil, Katgı, Nuran · 2022 · Molecular Imaging and Radionuclide Therapy
49. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
    2015 · Europe PMC (PubMed Central)